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Thrombotic thrombocytopenic purpura (TTP) is a multisystemic disorder characterized by microangiopathic hemolytic anemia
and thrombocytopenia, which may be accompanied by fever, renal, or neurologic abnormalities. Cases are divided into acute
idiopathic TTP and secondary TTP. Autoimmune diseases, especially systemic lupus erythematosus, in association with TTP have
been described so far in many patients. In contrast, TTP occurring in a patient with mixed connected tissue disease (MCTD)
is extremely rare and has only been described in nine patients. We describe the case of a 42-year-old female with MCTD who
developed thrombocytopenia, microangiopathic hemolytic anemia, fever, and neurological symptoms. The patient had a good
clinical evolution with infusion of high volume of fresh frozen plasma, steroid therapy, and support in an intensive care unit.
Although the occurrence of TTP is rare in MCTD patients, it is important to recognize TTP as a cause of thrombocytopenia and
hemolytic anemia in any patient with autoimmune diseases. Prompt institution of treatment remains the cornerstone of treatment
of TTP even if plasma exchange is not available like what frequently happens in developing countries.
1.Introduction
Thromboticthrombocytopenicpurpura(TTP)isamultisys-
temic disorder characterized by microangiopathic hemolytic
anemia and thrombocytopenia, which may be accompanied
byfever,renal,orneurologicabnormalities[1,2].Itisalmost
always acquired, with rare cases of congenital TTP (Upshaw-
Schulman syndrome). Acquired cases are divided into acute
idiopathic TTP and secondary TTP, which has been seen
in association with collagen vascular disease, bone mar-
row transplantation, malignancy, pregnancy, infections, and
drugs such as cyclosporine, tacrolimus, ticlopidine, and anti-
neoplasticagents[1,3].Systemiclupuserythematosus(SLE),
antiphospholipid antibody syndrome, adult onset Still’s
disease, systemic sclerosis, polymyositis, dermatomyositis,
and rheumatoid arthritis in association with TTP have been
described so far in many patients [4–12]. In contrast, mixed
connected tissue disease (MCTD) in association with TTP is
extremely rare and has only been described in nine patients
[13–21]. Here, we describe the 10th case of mixed connective
tissue disease (MCTD) complicated by TTP and discuss the
complexity of its management in a developing country.
2.CaseReport
A 42-year-old Afro-Brazilian woman was admitted to emer-
gency department with gradual neurologic disorientation,
associated with severe headache and episodes of vomiting
for three days. The patient had a past history of mixed con-
nective tissue disease (MCTD) for 4 years. Her clinical
presentation included Raynaud’s phenomenon associated
with puﬀy ﬁngers, arthralgias, mild arthritis (nonerosive
and nondeforming), and myalgia. She also had a pericardial
eﬀusion 3 years ago that seems to be related to MCTD.
Laboratory studies revealed that the patient had an ESR of2 Case Reports in Medicine
70mm/hr, positive rheumatoid factor (titre >128), positive
ANA (1:1280) with speckled pattern, and positive anti-U1-
RNP (>240U/mL). Anti-DNA, Anti-SM, Anti-CCP, Anti-
Jo1, Anti-SS-A, Anti-SS-B, Anti-SCL-70, Anticentromere,
ANCA, and Anticardiolipin were negative. She reported hav-
ing used only prednisone for the treatment of MCTD, cur-
rently using 10mg/kg/day. She also had hypertension on
regular treatment for the last 10 years.
On admission she was awake, dehydrated (+/4+), pale
(2+/4+), confused, and disorientated with a Glasgow coma
scale of 13 points and without focal neurologic deﬁcit. The
blood pressure was 180/100mmHg, pulse 108 per min. and
temperature 37.2◦C. Clinical examinations of the cardiovas-
cular, respiratory systems, and abdomen were normal. There
was edema in the lower limbs (2+/4+). Complete blood
cell count showed a normocytic normochromic anemia and
thrombocytopenia (Table 1). Peripheral blood smear dem-
onstrated anisocytosis, poikilocytosis with schistocytes, and
thrombocytopenia (Figure 1). Biochemical analysis revealed
elevatedlevelsofserumLDH(1,830U/L)andbilirubin(total
4.1mg/dL, direct 2.1mg/dL and indirect 2.0mg/dL). Direct
Coombs test was negative, and PT and aPTT were normal.
Her urine exam was positive to protein (3+), leukocyte (2+),
hemoglobin, (4+), bilirubin (1+), and urobilinogen (2+)
with negative nitrite. Other laboratory data are summarized
in Table 1.
Clinicalidentiﬁcationofnonimmunehaemolyticanemia
with presence of red cell fragmentation, thrombocytopenia,
and altered level of consciousness led to the diagnosis of
thrombotic thrombocytopenic purpura secondary to au-
toimmune disease, since the patient was previously di-
agnosed as MCTD. Prednisone 1mg/kg/day (80mg/day)
scheme was initiated after administration of antiparasitic
therapy (prophylaxis of strongyloides hyperinfection syn-
drome [22]), fresh frozen plasma (15mL/kg/day), and red
blood cells transfusion with blood pressure monitoring and
use of diuretics to prevent ﬂuid overload.
She evolved in 24 hours with high fever (39.2◦C); blood
pressure was 160/80mmHg, and subsequently, with de-
creased level of consciousness, she underwent endotracheal
intubation and was transferred to the Intensive care unit
(ICU). The infusion of fresh frozen plasma was progressively
increased to 25–30mL/kg/day. During hospitalization, she
presented with pneumonia and received ceftriaxone and
clindamycin. Abdominal ultrasonography, computed to-
mography, and magnetic resonance imaging of the brain
showed no speciﬁc abnormalities.
After 5 days in the ICU, she showed good clinical out-
come, with improvement of neurologic and respiratory pa-
rameters, allowing weaning and withdraw of mechanical
ventilation. Throughout the period her blood pressure was
kept under strict control with captopril, amlodipine, aten-
olol, methyldopa, and losartan, as well as periods of sodium
nitroprusside.
After 20 days of hospitalization, the patient pre-
sented progressive improvement in microangiopathic ane-
mia, increased haemoglobin, and platelets, and a progressive
decrease of LDH and reticulocytes (Table 1). She was not
submitted to plasmapheresis. There was normalization of
Figure 1: Blood Smear with anisocytosis, poikilocytosis, polychro-
matophilia (polychromasia) with schistocytes, and thrombocytope-
nia (1000x).
blood pressure with concomitant gradual reduction in the
volumeoffreshfrozenplasmainfusedandreductionofpred-
nisone. She was discharged from the hospital with antihy-
pertensive drugs (clonidine and amlodipine) and prednisone
(20mg/day). After 40 days of symptom onset and 20 days
after discharge the patient was asymptomatic and laboratory
tests improved (Table 1).
3. Discussion
Following the discovery that TTP is associated with a severe
deﬁciency of ADAMTS13 activity [23, 24], it was suggested
that ADAMTS13 deﬁciency may become the deﬁnition
and diagnostic criterion for TTP. But many patients who
fulﬁll the clinical diagnostic criteria for TTP do not have
ADAMTS13 deﬁciency [10, 25]. For some authors, mea-
surements of ADAMTS13 activity are not required and do
not conclusively conﬁrm the diagnosis of TTP [26]. In this
way, the diagnosis of TTP is based on the presenting clinical
features [1]. Prompt diagnosis of TTP is critical to begin
treatment and reduce patient’s mortality.
Patients diagnosed with TTP may have additional disor-
ders including autoimmune diseases. In this group systemic
lupus erythematosus (SLE) is the most common, followed
by antiphospholipid antibody syndrome, adult onset Still’s
disease,rheumatoidarthritis,systemicsclerosis,polymyositis
and dermatomyositis [4–12].
TTP associated with mixed connected tissue disease is
rare and has only been described in nine patients (Table 2)
[13–21]. Most of these cases were women (8:1) with the
median age of 40 years. The mortality was high (45%), early,
(within 2–45 days) and associated with serious neurological
impairment (seizure and coma). Our case presented a
good clinical evolution in spite of serious neurological
manifestations which points to a worse prognosis [17, 19].
The pathogenic processes of thrombotic microangiopa-
thy in patients with connective tissue diseases are heteroge-
neous. ADAMTS13 activity is signiﬁcantly decreased in this
group of patients. However, only a minor population pre-
sents neutralising autoantibodies against ADAMTS13, which
was associated with severe ADAMTS13 deﬁciency, lowerCase Reports in Medicine 3
Table 1: Laboratory data.
On admission After 20 days After 40 days
Complete blood count
RBC (×1012/L) 2.88 3.97 4.55
Hemoglobin (g/dL) 7.8 11.5 12.4
Hematocrit (%) 23.8 35 39.6
MCV (fL) 82.6 88 87
MCH (pg) 27 29 27
MCHC (g/dL) 32.7 33 31
RDW (%) 21.2 17.6 13.2
WBC (×109/L) 9.8 5.72 7.23
Platelet (×109/L) 5.1 243 312
Reticulocytes (%) 8.4 1.1 0.8
Blood chemistry
AST (IU/L) 46 22 21
ALT (IU/L) 43 29.2 31
GGT (IU/L) 98 230 80
ALP (IU/L) 98 130 72
LDH (IU/L) 1830 365 176
Total bilirubin (mg/dL) 4.1 0.5 0.6
Direct bilirubin (mg/dL) 2.1 0.23 0.28
Indirect bilirubin (mg/dL) 2 0.27 0.32
Glucose (mg/dL) 128 98 89
Urea (mg/dL) 19
Creatinine (mg/dL) 0.6
Uric acid (mg/dL) 3.0
Sodium (mEq/L) 139
Potassium (mEq/L) 2.9
Hormones
TSH (µU/mL) 2.72
Free T4 (pg/dL) 1.08
Serology
HBsAg Negative
Anti-HBs Negative
Anti-HBc Negative
Anti-HCV Negative
Anti-HIV Negative
Blood culture Negative
Other blood tests
ESR (mm/hr) 78
PT (s) 10.2
aPTT (s) 21.3
Direct Coobs test Negative
Urinalysis
Protein (3+)
Leukocyte (2+)
Hemoglobin (4+)
Bilirubin (1+)
Urobilinogen (2+)
Nitrite (—)
Urine culture negative
RBC: red blood cells, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, RDW:
red blood cell distribution width, WBC: white blood cells, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, GGT:
gamaglutamil transferase, LDH: lactate dehydrogenase, ESR: erythrocyte sedimentation rate, PT: prothrombin time, ATTP: activated partial thromboplastin
time, TSH: Thyroid-stimulating hormone.4 Case Reports in Medicine
Table 2: Characteristics of TTP in patients with MCTD.
Age Sex Duration of
MTCD(years) Prodrome Treatment Prognosis Reference
29 F 5 Chest pain, fever, loin pain, confusion PDN Died (2 days) [13]
33 F 2 Flu-like syndrome PDN, FFP, vincristin, prostacyclin Alive [14]
40 F 2 Headache, confusion, seizure PE, PDN, vincristin, aspirin Died (12 days) [15]
55 F ? Fever, confusion, seizure, coma,
myocardial infarction PE, PDN Alive [16]
64 F 8 Headache, confusion seizure, coma PE, PDN Died (45 days) [17]
15 M ? Headache, visual blurring, vomiting,
Paresthesia PE, PDN, vincristin, cyclosporine Alive [18]
73 F 10 Confusion, coma PE, PDN Died (34 days) [19]
46 F 2 Fever, headache PE, PDN, aspirin,
Cyclophosphamide, rituximab Alive [20]
24 F <1 Laboratory detection PE Alive [21]
42 F 4 Headache, confusion seizure, coma,
Fever, vomiting, hematuria FFP, PDN Alive This case
F: female, M: male, PDN: prednisone or prednisolone, FFP: fresh frozenplasma, PE: plasma exchange.
platelet counts, and better therapeutic outcomes. A major
population has normal or moderately reduced ADAMTS13
activity [4]. In this group, the mechanisms of development
of TTP remain unclear. There is a higher prevalence of anti-
endothelial cell antibodies in the sera of MCTD patients [27]
and depressed plasma ﬁbrinolytic activity [28], suggesting
that a MCTD related vasculitis and thrombotic microan-
giopathy may have been involved in the pathogenesis of
TTP [15, 17]. In patients with systemic sclerosis, renal crisis
remains one of the potential processes related to microan-
giopathic hemolytic anemia, thrombocytopenia, accelerated
hypertension and acute renal failure [29, 30].
Previous reported cases were treated with various ther-
apies including steroids, fresh frozen plasma (FFP), plasma
exchange (PE), prostacyclin, vincristine, cyclosporine, cyclo-
phosphamide, rituximab and aspirin [13–21]. Today, the
mainstay of treatment of acute TTP is plasma exchange
[1]. Before the plasma treatment era, survival of patients
with TTP was only 10%. Then, almost 20 years ago, plasma
exchangewasreportedtoincreasesurvivalto78%,compared
to 51% survival for patients treated with plasma infusion
[31]. Nowadays, however, there are some places that plasma
exchange still unavailable. In these cases, high volume of
plasma infusion (30mL/kg/d) may be indicated if there is
to be an unavoidable delay in plasma exchange [1, 32, 33].
Adjuvant corticosteroid treatment is also used with the
intention to suppress the activity of auto-antibodies against
ADAMTS13 [1, 26].
The clinical team’s intention was to transfer the patient
to start plasmapheresis, but by the critical condition, it was
not possible immediately. So, we started FFP infusion and
immunosuppression with prednisone 1mg/kg/day and the
patient gradually improved. The high volume of fresh frozen
plasma could only be provided because of patient’s good
cardiac and renal function associated with a strict blood
pressure control.
4. Conclusion
Although the occurrence of TTP is rare in MCTD patients,
it is important to recognize TTP as a cause of thrombocy-
topenia and hemolytic anemia in any patient with autoim-
mune diseases. Prompt institution of treatment remains the
cornerstone of treatment of TTP even if plasma exchange
is not available like what frequently happens in developing
countries.
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